{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:17:05Z","timestamp":1790713025695,"version":"4.1.0"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>OBJECTIVES:<\/jats:title>\n            <jats:p>Protein binding of valproate is variable in ICU patients, and the total valproate concentration does not predict the free valproate concentration, even when correcting for albumin. We sought to quantify valproate free concentration among ICU patients, identify risk factors associated with an increasing free valproate concentration, and evaluate the association between free valproate concentration with potential adverse drug effect.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>DESIGN:<\/jats:title>\n            <jats:p>Retrospective multicenter cohort study.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>SETTING:<\/jats:title>\n            <jats:p>Two academic medical centers.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>PATIENTS:<\/jats:title>\n            <jats:p>Patients greater than or equal to 18 years of age with concomitant free and total valproate concentrations collected in the ICU.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>INTERVENTIONS:<\/jats:title>\n            <jats:p>None.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>MEASUREMENTS AND MAIN RESULTS:<\/jats:title>\n            <jats:p>Two-hundred fifty-six patients were included in the study, with a median age of 56 years (42\u201370) and 65% of patients were male. The median total valproate concentration was 53 \u00b5g\/mL (38\u201370 \u00b5g\/mL), the free valproate concentration was 12 \u00b5g\/mL (7\u201320 \u00b5g\/mL), and the free fraction was 23.6% (17.0\u201333.9%). Therapeutic discordance between the free and total valproate concentration occurred in 70% of patients. On multivariable analysis, increased free valproate concentration was associated with higher total valproate concentration (per 5 \u00b5g\/mL increase, increase 1.72 \u00b5g\/mL, 95% CI, 1.48\u20131.96) and lower serum albumin (per 1\u2009g\/dL decrease, increase 4.60 \u00b5g\/mL, 95% CI, 2.71\u20136.49). There was no association between free valproate concentration and adverse effects.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSIONS:<\/jats:title>\n            <jats:p>The valproate total and free concentration was discordant in the majority of patients (70%). Increased valproate free concentration was associated with hypoalbuminemia and total valproate concentration. Clinical decisions based on total valproate concentration may be incorrect for many ICU patients. Prospective, controlled studies are needed to confirm these findings and their clinical relevance.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/cce.0000000000000746","type":"journal-article","created":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T15:01:13Z","timestamp":1662994873000},"page":"e0746","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":8,"title":["Evaluation of Free Valproate Concentration in Critically Ill Patients"],"prefix":"10.1097","volume":"4","author":[{"given":"Caitlin S.","family":"Brown","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Mayo Clinic, Rochester, MN."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JiTong","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Beth Israel Deaconess Medical Center, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard R.","family":"Riker","sequence":"additional","affiliation":[{"name":"Department of Critical Care Services, Maine Medical Center, Portland, ME."},{"name":"Tufts University School of Medicine, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin C.","family":"Mara","sequence":"additional","affiliation":[{"name":"Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro A.","family":"Rabinstein","sequence":"additional","affiliation":[{"name":"Division of Neurology, Mayo Clinic, Rochester, MN."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles L.","family":"Fraser","sequence":"additional","affiliation":[{"name":"(ret.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa L.","family":"May","sequence":"additional","affiliation":[{"name":"Department of Critical Care Services, Maine Medical Center, Portland, ME."},{"name":"Tufts University School of Medicine, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Seder","sequence":"additional","affiliation":[{"name":"Department of Critical Care Services, Maine Medical Center, Portland, ME."},{"name":"Tufts University School of Medicine, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Gagnon","sequence":"additional","affiliation":[{"name":"Tufts University School of Medicine, Boston, MA."},{"name":"Department of Pharmacy, Maine Medical Center, Portland, ME."},{"name":"Maine Medical Center Research Institute, Portland, ME."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,9,7]]},"reference":[{"key":"R1-20240807","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1002\/phar.2017","article-title":"Repurposing valproate, enteral clonidine, and phenobarbital for comfort in adult ICU patients: A literature review with practical considerations.","volume":"37","author":"Gagnon","year":"2017","journal-title":"Pharmacotherapy"},{"key":"R2-20240807","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/j.1528-1167.2008.01561.x","article-title":"Antiepileptic drugs\u2014best practice guidelines for therapeutic drug monitoring: A position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies.","volume":"49","author":"Patsalos","year":"2008","journal-title":"Epilepsia"},{"key":"R3-20240807","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1002\/phar.1912","article-title":"Valproate protein binding is highly variable in ICU patients and not predicted by total serum concentrations: A case series and literature review.","volume":"37","author":"Riker","year":"2017","journal-title":"Pharmacotherapy"},{"key":"R4-20240807","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.1528-1157.1982.tb06193.x","article-title":"Diurnal oscillations in plasma protein binding of valproic acid.","volume":"23","author":"Patel","year":"1982","journal-title":"Epilepsia"},{"key":"R5-20240807","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/00007691-198004000-00015","article-title":"Monitoring of free valproic acid levels?","volume":"2","author":"Levy","year":"1980","journal-title":"Ther Drug Monit"},{"key":"R6-20240807","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1111\/j.1445-5994.1987.tb01259.x","article-title":"Plasma concentrations of unbound valproate and the management of epilepsy.","volume":"17","author":"Kilpatrick","year":"1987","journal-title":"Aust N Z J Med"},{"key":"R7-20240807","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1212\/WNL.42.5.988","article-title":"Clinical utility of unbound antiepileptic drug blood levels in the management of epilepsy.","volume":"42","author":"Lenn","year":"1992","journal-title":"Neurology"},{"key":"R8-20240807","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1248\/bpb.35.971","article-title":"Correlation between plasma ammonia level and serum trough concentration of free valproic acid in patients with epilepsy.","volume":"35","author":"Itoh","year":"2012","journal-title":"Biol Pharm Bull"},{"key":"R9-20240807","doi-asserted-by":"crossref","first-page":"e0238201","DOI":"10.1371\/journal.pone.0238201","article-title":"Safety range of free valproic acid serum concentration in adult patients.","volume":"15","author":"Tseng","year":"2020","journal-title":"PLoS One"},{"key":"R10-20240807","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.seizure.2007.12.007","article-title":"Value of therapeutic drug level monitoring and unbound (free) levels.","volume":"17","author":"Chan","year":"2008","journal-title":"Seizure"},{"key":"R11-20240807","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jcrc.2016.09.006","article-title":"Valproate for agitation in critically ill patients: A retrospective study.","volume":"37","author":"Gagnon","year":"2017","journal-title":"J Crit Care"},{"key":"R12-20240807","doi-asserted-by":"crossref","first-page":"A80","DOI":"10.1016\/j.resuscitation.2020.09.012","article-title":"Adult advanced life support: 2020 international consensus on cardiopulmonary resuscitation and emergency cardiovascular care science with treatment recommendations.","volume":"156","author":"Soar","year":"2020","journal-title":"Resuscitation"},{"key":"R13-20240807","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1097\/FTD.0000000000000903","article-title":"Determination of free valproic acid concentration in 569 clinical samples by LC-MS\/MS after hollow fiber centrifugal ultrafiltration treatment.","volume":"43","author":"Wu","year":"2021","journal-title":"Ther Drug Monit"},{"key":"R14-20240807","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2146\/ajhp140191","article-title":"Comparison of free fraction serum valproic acid concentrations between inpatients and outpatients.","volume":"72","author":"Gibbs","year":"2015","journal-title":"Am J Health Syst Pharm"},{"key":"R15-20240807","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1056\/NEJMra071313","article-title":"Uremia.","volume":"357","author":"Meyer","year":"2007","journal-title":"N Engl J Med"},{"key":"R16-20240807","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/j.1365-2125.1978.tb01652.x","article-title":"Plasma protein binding of valproic acid in healthy subjects and in patients with renal disease.","volume":"5","author":"Gugler","year":"1978","journal-title":"Br J Clin Pharmacol"},{"key":"R17-20240807","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/clpt.1982.89","article-title":"Interaction between valproic acid and aspirin in epileptic children: Serum protein binding and metabolic effects.","volume":"31","author":"Orr","year":"1982","journal-title":"Clin Pharmacol Ther"},{"key":"R18-20240807","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1176\/ajp.2006.163.11.1891","article-title":"An interaction between aspirin and valproate: The relevance of plasma protein displacement drug-drug interactions.","volume":"163","author":"Sandson","year":"2006","journal-title":"Am J Psychiatry"},{"key":"R19-20240807","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2165\/00003495-198019010-00003","article-title":"The pharmacological role of the kidney.","volume":"19","author":"Brater","year":"1980","journal-title":"Drugs"}],"container-title":["Critical Care Explorations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CCE.0000000000000746","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T14:35:36Z","timestamp":1723041336000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CCE.0000000000000746"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":19,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/cce.0000000000000746","relation":{},"ISSN":["2639-8028"],"issn-type":[{"value":"2639-8028","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9]]}}}